期刊
CANCER LETTERS
卷 376, 期 1, 页码 118-126出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.03.030
关键词
ABCG2 transporter; Multidrug resistance; Cytotoxicity; Chemosensitivity; Novel MDR modulators
类别
资金
- University of Toledo start-up grant [F110760]
- Tuskegee RCMI Core grant [G12MD007585-23]
- IBS-REU program
- MSM/TU/UAB Comprehensive Cancer Center Partnership [NCI] [U54 CA118623]
- Auburn University Research Initiative in Cancer [101069-139268-2052]
- Animal Health and Disease Research Grants [101002-139268-2055]
Overexpression of ATP-binding cassette transporter (ABC) subfamily G2 in cancer cells is known to elicit a MDR phenotype, ultimately resulting in cancer chemotherapy failure. Here, we report, for the first time, the effect of eight novel pyrimido[1,2:1,5]pyrazolo[3,4-b]quinoline (IND) derivatives that inhibit ABCG2 transporter restoring cancer cell chemosensitivity. IND -4, -5, -6, -7, and -8, at 10 mu M, and nilotinib at 5 mu M, significantly potentiated (8-10 fold) the cytotoxicity of the ABCG2 substrates mitoxantrone (MX) and doxorubicin in HEK293 cells overexpressing ABCG2 transporter, MX (similar to 14 fold) in MX-resistant NCI-H460/MX-20 small cell lung cancer, and of topotecan (similar to 7 fold) in S1-M1-80 colon cancer cells which all stably expressing ABCG2. In contrast, cytotoxicity of cisplatin, which is not an ABCG2 substrate, was not altered. IND-5,-6,-7, and -8 significantly increased the accumulation of rhodamine-123 in multidrug resistant NCI-H460/MX-20 cells overexpressing ABCG2. Both IND-7 and -8, the most potent ABCG2 inhibitors, had the highest affinities for the binding sites of ABCG2 in modeling studies. In conclusion, the beneficial actions of new class of agents warrant further development as potential MDR reversal agents for clinical anticancer agents that suffer from ABCG2-mediated MDR insensitivity. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据